Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging
Vol. 17 No. 4 (2020),
24 June 2020
Purpose: Prostate cancer is a major worldwide health concern with up to 60% of patients experiencing biochemical relapse after radical treatment. Introduction of prostate-specific membrane antigen (PSMA)-based radiotracers for imaging and therapy had gained increasing attention in recent years. Positron emission tomography (PET) imaging with Ga68 PSMA is the most promising technique, but PSMA-based radiotracers SPECT imaging with low dose of 177Lu-PSMA when PET imaging is not available may also be considered. The goal of the study is to evaluate the sensitivity of 177Lu_psma for detection of metastatic sites in patients with biochemical relapse and negative conventional (MRI, MRS, CT scan and bone scintigraphy) imaging.
Materials & methods: 26 patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy, which had previous negative imaging as pelvic CT scan, pelvic MRI, MRS and bone scan, were enrolled in this clinical imaging approach between 2015 and 2017.After injection of 5 mCi (185MBq)177Lu-PSMA-617, diagnostic planar whole body scan and SPECT study was obtained after 3 hours, 24 hours and 72 hours. The images were analyzed visually by an expert nuclear medicine physician for the presence of active regional or distant lesions. Results were then prospectively checked by new CT scan images as a control.
Result: A total of 26 patients, with a mean age of 70 years (range: 46 to 89 years) were included in this study. The overall detection rates were 38.5% (10 out of 26 patients). Most common site of detected lesions was lung in 6 patients, abdominal lymph nodes in 2 and mediastinum in another 2 patients.
Conclusion: 177Lu-PSMA SPECT scan can help detecting metastatic lesions in more than one third of patients
with biochemical recurrence and negative conventional investigations, when 68Ga- PSMA PET is not available.
How to Cite
Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016;57(Suppl 3):79S-89S.
Kurreck A, Vandergrift LA, Fuss TL, Habbel P, Agar NYR, Cheng LL. Prostate cancer diagnosis and characterization with mass spectrometry imaging. Prostate Cancer Prostatic Dis. 2018;21(3):297-305.
Yajun C, Yuan T, Zhong W, Bin X. Investigation of the molecular mechanisms underlying postoperative recurrence in prostate cancer by gene expression profiling. Exp Ther Med. 2018;15(1):761-8.
Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol Int. 2018;100(3):251-62.
Sarkar S, Das SJBe, biology c. A Review of Imaging Methods for Prostate Cancer Detection: Supplementary Issue: Image and Video Acquisition and Processing for Clinical Applications. 2016;7:BECB. S34255.
Grubmuller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, et al. (68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. European journal of nuclear medicine and molecular imaging. 2018;45(2):235-42.
Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477-88.
Ahmadzadehfar H, Essler M. Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing (177)Lu-PSMA therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018.
Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI research. 2015;5(1):114.
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016;57(7):1006-13.
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Journal of medical radiation sciences. 2017;64(1):52-60.
Miller ET, Salmasi A, Reiter RE. Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med. 2018;8(3).
Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, et al. Diagnosis of local recurrence after radical prostatectomy. 2004;93(5):680-8.
Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. Diagnostics (Basel). 2018;8(1).
Evangelista L, Sepulcri M, Maruzzo M. Prostate cancer imaging: when the game gets tough, the hard one gets done! Eur J Nucl Med Mol Imaging. 2018.
Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, et al. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Molecular imaging and radionuclide therapy. 2017;26(2):62-8.
Reinstatler L, Dupuis J, Dillon JL, Black CC, Phillips JD, Hyams ESJUcr. Lung malignancy in prostate cancer: A report of both metastatic and primary lung lesions. 2018;16:119.
- Abstract Viewed: 220 times
- pdf/5451 Downloaded: 96 times